Omada Health, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $260.2M | $169.8M | $122.8M |
| Cost of Revenue | $89.3M | $66.9M | $52.8M |
| Gross Profit | $170.9M | $102.9M | $70.0M |
| Gross Margin | 65.7% | 60.6% | 57.0% |
| Operating Expenses | |||
| Research & Development | $40.7M | $35.9M | $33.7M |
| SG&A Expense | $52.2M | $42.6M | $36.0M |
| Operating Income | $-12.0M | $-43.7M | $-66.0M |
| Operating Margin | -4.6% | -25.7% | -53.8% |
| Interest Expense | — | — | — |
| Pretax Income | $-12.8M | $-47.1M | $-67.5M |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $-12.8M | $-47.1M | $-67.5M |
| Net Margin | -4.9% | -27.8% | -55.0% |
| EPS (Basic) | $-0.35 | $-1.22 | $-1.90 |
| EPS (Diluted) | $-0.35 | $-1.22 | $-1.90 |
| Shares Outstanding (Basic) | 36.6M | 38.6M | 35.5M |
| Shares Outstanding (Diluted) | 36.6M | 38.6M | 35.5M |
| Dividends Per Share | — | — | — |